

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC.,
Petitioner

v.

GILEAD PHARMASSET LLC,
Patent Owner.

Case IPR2018-00390
Patent 8,889,159 B2

Before ERICA A. FRANKLIN, GRACE KARAFFA OBERMANN
and RICHARD J. SMITH, *Administrative Patent Judges*.

OBERMANN, *Administrative Patent Judge*.

DECISION
Denying Institution of *Inter Partes* Review
35 U.S.C. § 314(a)

I. INTRODUCTION

Petitioner filed a Petition for *inter partes* review of claims 1–37 of U.S. Patent 8,889,159 B2 (“the ’159 patent”). Paper 2 (“Pet.”). Patent Owner filed a Preliminary Response. Paper 6 (“Prelim. Resp.”). We have authority to institute an *inter partes* review only upon a showing that Petitioner is reasonably likely to prevail with respect to at least one challenged patent claim. 35 U.S.C. § 314(a). Applying that standard, we conclude that Petitioner has not established the threshold showing for review and, accordingly, we deny the Petition and do not institute review of any challenged claim.

A. *Related Proceedings*


Petitioner identifies as a related matter a pending patent application (U.S. Patent Appl. No. 15/410,438) that claims priority through the ’159 patent. Pet. 2. Petitioner avers that it “is not aware of any other matter that would affect, or be affected by, a decision in this proceeding.” *Id.*

Patent Owner identifies the same pending application under a heading titled “Related Matters.” Paper 3, 2. Patent Owner also identifies a second pending application (U.S. Patent Appl. No. 14/538,736) as a related matter and, further, “notes” that Petitioner filed eight prior petitions for *inter partes* review, none of which was directed to any claims of the ’159 patent. *Id.* at 2–3 (citations omitted). “Patent Owner does not concede that any” of those identified matters— “aside from” the ’159 patent—“would affect, or be affected by this proceeding.” *Id.*

B. The '159 Patent

The '159 patent relates to a pharmaceutical composition and unit dosage form of a specific agent for treating hepatitis C virus (“HCV”). Ex. 1001, Abstract. The specification discloses that (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate is “available from Gilead Sciences, Inc.” and, further, is disclosed and claimed in U.S. Pat. No. 7,964,580. Ex. 1001, 7:65–8:2.

The specification states that this HCV agent is, or has been, known variously as “GS-7977,” “sofosbuvir,” and “PSI-7977.” *Id.* at 7:67; 5:20–21. We refer to that agent in this decision as sofosbuvir. According to the '159 patent specification, sofosbuvir has the following general structure:



Id. at 7:65–8:15. Patent Owner directs us to information that sofosbuvir may exist in different crystalline forms known as “polymorphs,” which “can, and often do, exhibit different properties.” Prelim. Resp. 5–6 (and evidence cited therein).

The '159 patent discloses a polymorphic form of sofosbuvir identified as “Form 6.” Ex. 1001, 8:42; 32:24, 31. According to the specification, Form 6 is

characterized by an X-ray powder diffraction (“XRPD”) pattern of “2 θ -reflections ($^{\circ}$) at about: 6.1, 8.2, 10.4, 12.7, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.” *Id.* at 8:18–26, 40–56; *see id.* at 9:51–55 (disclosing “preferred subembodiment” of “crystalline” sofosbuvir having that characteristic XRPD pattern of 2 θ -reflections); 11:40–12:55 (disclosing embodiments having that characteristic XRPD pattern of 2 θ -reflections).


The specification discloses an example that includes instructions for forming “polymorphic Form 6” into a 400 mg tablet dosage form. *Id.* at 32:6–63. Specifically, the ’159 patent describes milling Form 6 “with extragranular excipients (microcrystalline cellulose, croscarmellose sodium, colloidal silicon [dioxide], magnesium stearate) to yield a powder blend comprising 33.33% w/w” sofosbuvir, which “was compressed to a target tablet weight of 1200 mg, with each tablet comprising about 400 mg of” sofosbuvir. *Id.* Patent Owner avers that Form 6 is used in its commercial pharmaceutical product known as Sovaldi. Prelim. Resp. 6.

C. Illustrative Claims

Petitioner challenges claims 1–37 of the ’159 patent, of which claims 1 and 16 are the only independent claims.

Claim 1 is reproduced below:

1. A pharmaceutical composition comprising:
a) about 25% to about 35% w/w of crystalline GS-7977
having the structure



and

- b) at least one pharmaceutically acceptable excipient,
wherein the crystalline GS-7977 has XRPD 2 θ -reflections
($^{\circ}$) at about:
6.1 and 12.7.

Ex. 1001, 46:36–56. Claims 2–15 and 33 depend directly or indirectly from claim 1. *Id.* at 46:57–47:50; 49:15–17.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.